Indivior PLC
NASDAQ:INDV

Watchlist Manager
Indivior PLC Logo
Indivior PLC
NASDAQ:INDV
Watchlist
Price: 33.24 USD -0.89% Market Closed
Market Cap: $4.2B

Net Margin

4.6%
Current
Declining
by 0.1%
vs 3-y average of 4.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
4.6%
=
Net Income
$70m
/
Revenue
$2.1B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
4.6%
=
Net Income
$70m
/
Revenue
$2.1B

Peer Comparison

Country Company Market Cap Net
Margin
UK
Indivior PLC
LSE:INDV
1.5B GBP
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

Higher than 96% of companies in United Kingdom
Percentile
96th
Based on 3 670 companies
96th percentile
4.6%
Low
-188 120% — 0%
Typical Range
0% — 0.1%
High
0.1% — 10 443.9%
Distribution Statistics
United Kingdom
Min -188 120%
30th Percentile 0%
Median 0%
70th Percentile 0.1%
Max 10 443.9%

Indivior PLC
Glance View

Indivior PLC, a pivotal player in the pharmaceutical landscape, traces its roots back to a dedicated focus on addiction treatment. With an origin steeped in addressing opioid dependency, the company carved out a significant niche by developing and marketing medication-assisted treatments. At the heart of Indivior's success is its flagship product, Suboxone, which combines buprenorphine and naloxone to manage opioid addiction. This formulation, integral in combating withdrawal symptoms and reducing the allure of opioids, positioned Indivior as an innovator in an era when the opioid crisis commanded urgent attention. The company's revenue model leverages the growing need for comprehensive drug dependence solutions, primarily driven by its robust portfolio of treatment options. By relentlessly advocating for effective healthcare policies and ensuring substantial product availability, Indivior maintains its competitive edge. The company's strategy is not just confined to novel drug development, but also focuses on expanding treatment access globally, aligning profitability with public health imperatives. This dual commitment to innovation and societal impact ensures that Indivior remains a significant force in the healthcare sector, adeptly navigating the complexities of addiction treatment while generating sustainable financial growth.

INDV Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
4.6%
=
Net Income
$70m
/
Revenue
$2.1B
What is Indivior PLC's current Net Margin?

The current Net Margin for Indivior PLC is 4.6%, which is below its 3-year median of 4.7%.

How has Net Margin changed over time?

Over the last 0 months, Indivior PLC’s Net Margin has decreased from 4.7% to 4.6%. During this period, it reached a low of 4.7% on Jun 30, 2025 and a high of 4.7% on Jun 30, 2025.

Back to Top